AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26794905
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing of celgosivir starting on day 3
Trial: 26794905
Drug: Four-times daily
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-times daily treatment of celgosivir
Trial: 26795844
Drug: 3×150 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3×150 μg/kg ondansetron
Trial: 26796402
Drug: P-Selectin Antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-Selectin Antagonist Inclacumab
Trial: 26796810
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of 100 μg/kg pegylated filgrastim
Trial: 26796810
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections of 5 μg/kg filgrastim
Trial: 26797207
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral co-formulated tenofovir/emtricitabine (PrEP)
Trial: 26798977
Drug: Corticosteroid implant
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid implant
Trial: 26799743
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks
Trial: 26800632
Drug: Psychological attribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological attribution and emotional awareness and expression therapy
Trial: 26800997
Drug: 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg of ramosetron for 4 weeks, continued for another 48 weeks for responders
Trial: 26800997
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg of ramosetron for 48 weeks for non-responders
Trial: 26803277
Drug: Ivacaftor 50
RxNorm normalized name: ivacaftor 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight ≥14 kg) every 12 h for 4 days (part A) and then for 24 weeks (part B)
Trial: 26803277
Drug: Ivacaftor 50
RxNorm normalized name: ivacaftor 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivacaftor 50 mg or 75 mg
Trial: 26803446
Drug: Ledipasvir-sofosbuvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir orally once per day for 12 weeks)
Trial: 26806010
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (600 mg fixed dose via SC single-use injection device)
Trial: 26806010
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (via SC handheld syringe)
Trial: 26808671
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg orally
Trial: 26809204
Drug: Illicit drug
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit drug use (e.g., marijuana, cocaine, heroin)
Trial: 26809204
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse
Trial: 26810441
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for allergic rhinitis
Trial: 26810581
Drug: Bi-weekly Pemetrexed
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly Pemetrexed (PEM) at 500 mg/m(2) combined with weekly Cisplatin (CDDP) and standard dose External Beam Radiation Therapy (EBRT)
Trial: 26810651
Drug: Rifampin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (two formulations)
Trial: 26812041
Drug: Weekly mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly mood monitoring and treatment target data
Trial: 26812512
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (EPA+DHA: 2.4 g/d)
Trial: 26814884
Drug: Balloon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon therapy for stress urinary incontinence
Trial: 26814884
Drug: Intravesical liposomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical liposomes for drug delivery in interstitial cystitis/painful bladder syndrome
Trial: 26817280
Drug: CsA dosage
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA dosage regimen based on urinary HOM
Trial: 26818566
Drug: Lopinavir/ritonavir-based antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir-based antiretroviral therapy with artemether-lumefantrine treatment
Trial: 26818566
Drug: Antiretroviral-naïve group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral-naïve group with artemether-lumefantrine treatment
Trial: 26818847
Drug: Robot walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot walking sessions for 45 min daily over 20 sessions
Trial: 26819296
Drug: Autologous mesenchymal
RxNorm normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous mesenchymal stromal cell (MSC) infusion, 2 infusions 1 week apart after 8 weeks of MSC culture expansion.
Trial: 26819296
Drug: Autologous MSC
RxNorm normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous MSC treatment
Trial: 26819724
Drug: Ibuprofen sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen sodium (2×256 mg, equivalent to 400 mg standard ibuprofen)
Trial: 26819724
Drug: Standard ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ibuprofen (2×200 mg)
Trial: 26819724
Drug: Standard ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ibuprofen
Trial: 26819724
Drug: Ibuprofen sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen sodium vs Standard ibuprofen
Trial: 26819748
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (TNFi + csDMARD such as methotrexate)
Trial: 26819748
Drug: Monotherapy (TNFi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (TNFi only)
Trial: 26819752
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy (arm M)
Trial: 26822149
Drug: Individualized cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized cancer therapy (iCat) recommendations based on tumor profiling
Trial: 26822149
Drug: Matched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched therapy based on iCat recommendations
Trial: 26822279
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg low-dose aspirin
Trial: 26822279
Drug: Higher-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose aspirin challenges (up to 325 mg)
Trial: 26823177
Drug: Pandemrix (adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemrix (adjuvanted A/H1N1 2009 pandemic influenza vaccine)
Trial: 26823971
Drug: Tac-OD (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tac-OD (once-daily tacrolimus)
Trial: 26824901
Drug: Intravesical injection
RxNorm normalized name: THIOTEPA 15 mg INTRAVESICAL INJECTION, POWDER, FOR SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical injection of 100 U onabotulinumtoxinA (Botox)
Trial: 26824940
Drug: i.v. acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. acyclovir, 5 mg/kg infused over 60 min (using ideal body weight for obese patients)
Trial: 26824940
Drug: i.v. acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. acyclovir, 5 mg/kg infused over 60 min (using total body weight for normal-weight patients)
Trial: 26825111
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection at baseline, treatment completion, and at a 3-month follow-up
Trial: 26825170
Drug: EGF816 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF816 + INC280 (cMET inhibitor)
Trial: 26825712
Drug: Defibrotide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 25 mg/kg per day
Trial: 26825925
Drug: nuMoM2b-HHS study
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nuMoM2b-HHS study visit including psychosocial and medical history questionnaires, clinical measurements, and biological specimens obtained.
Trial: 26829441
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of VLDL-TG secretion
Trial: 26829441
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of VLDL-TG oxidation
Trial: 26829441
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of VLDL-TG concentration
Trial: 26829441
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of VLDL particle size
Trial: 26829441
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of endogenous glucose production
Trial: 26830335
Drug: Antibiotics adapted
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics adapted to sputum colonization (cases)
Trial: 26830335
Drug: Oseltamivir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir treatment (cases)
Trial: 26830335
Drug: Antibiotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatments (cases)
Trial: 26830335
Drug: Antibiotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatments (controls)
Trial: 26830930
Drug: Literature review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literature review of effective PTSD treatments
Trial: 26831486
Drug: Fear of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fear of procedure and concern about taking a powerful laxative
Trial: 26831652
Drug: Albuterol MDPI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDPI with integrated dose counter (2 inhalations/dose; 90 μg/inhalation) twice daily for up to 50 days
Trial: 26831652
Drug: Albuterol MDPI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDPI with integrated dose counter
Trial: 26831844
Drug: budesonide/formoterol (160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol (160/4.5 μg, one inhalation twice daily and as needed)
Trial: 26832367
Drug: Serum 14-3-3η
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 14-3-3η protein levels ≥0.50 ng/ml
Trial: 26832367
Drug: Decreases of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreases of 14-3-3η levels by at least 0.76 ng/ml
Trial: 26832367
Drug: Baseline 14-3-3η
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline 14-3-3η ≥0.19 ng/ml
Trial: 26832367
Drug: Optimal baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal baseline 14-3-3η levels defined by ROC curves at 0.50 ng/ml
Trial: 26832753
Drug: Rifabutin at
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin at 150 mg once daily with non-boosted or ritonavir-boosted PIs
Trial: 26832753
Drug: Rifabutin at
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin at 300 mg every 3 days with boosted PI
Trial: 26834058
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg orally once per day
Trial: 26835148
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant (LAC) presence
Trial: 26835225
Drug: Afatinib 50
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 50 mg/day plus letrozole 2.5 mg/day
Trial: 26835225
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/day plus letrozole 2.5 mg/day
Trial: 26835225
Drug: Afatinib 30
RxNorm normalized name: afatinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 30 mg/day plus letrozole 2.5 mg/day
Trial: 26835906
Drug: Biologicals treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologicals treatment
Trial: 26836193
Drug: T3D-959 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3D-959 (0.3 to 3.0 mg/kg/day) for 28 days
Trial: 26836193
Drug: Lowest tested
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest tested dose of T3D-959
Trial: 26837432
Drug: Patient Directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Directed Activity Program (up to three additional 30-minute bouts of activities daily)
Trial: 26837440
Drug: NBS20/eltrapuldencel-T (dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBS20/eltrapuldencel-T (dendritic cell-based vaccine)
Trial: 26837440
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy and immunotherapy
Trial: 26838019
Drug: Fosaprepitant 150
RxNorm normalized name: fosaprepitant 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 150 mg IV on days 3 and 5, 5HT3 receptor antagonist days 1-5, dexamethasone 20 mg days 1 and 2, 4 mg po bid days 6, 7, and 8
Trial: 26839391
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of chronic total occlusion lesions
Trial: 26839475
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hemolysis and 1 or more clinical symptoms (abdominal pain, chest pain, dyspnea)
Trial: 26839476
Drug: Conventional cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cereal flakes (CC)
Trial: 26841930
Drug: Ledipasvir/sofosbuvir fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks
Trial: 26843355
Drug: Patch plasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch plasty
Trial: 26844278
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E δ-tocotrienol (VEDT) 200 to 3200 mg daily for 13 days before surgery and one dose on the day of surgery
Trial: 26844278
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E δ-tocotrienol (VEDT) 200 to 1600 mg daily for 2 weeks before pancreatic surgery
Trial: 26844479
Drug: Desensitization regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization regimen consisting of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m)
Trial: 26845282
Drug: Risperidone (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (administered for 6 weeks)
Trial: 26846166
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine (IM) approach, non-standardized and personalized, multimodal
Trial: 26847408
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of asthma and current ICS therapy
Trial: 26848057
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (50 mg dose)
Trial: 26849853
Drug: R-CHOP or
RxNorm normalized name: A.E.R. Witch Hazel Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP or R-CVP followed by (90) Y-IT (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab
Trial: 26850111
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) treatment administered by Korean medicine doctors (KMDs)
Trial: 26850678
Drug: KW-2450 40
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2450 40 mg/kg
Trial: 26850678
Drug: KW-2450 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2450 37.5 mg once daily continuously
Trial: 26850678
Drug: KW-2450 50
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2450 50 mg/day
Trial: 30446785
Drug: BEZ235 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 400 mg bid
Trial: 26851029
Drug: BEZ235 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 300 mg bid
Trial: 26852132
Drug: Anthracycline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline treatment (specifically epirubicin)
Trial: 26852132
Drug: Histone deacetylase
RxNorm normalized name: Histone deacetylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histone deacetylase small-molecule inhibitors
Trial: 26853249
Drug: Pre-hospital medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital medication (PHM)
Trial: 26854432
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies targeting castration-resistant prostate cancer
Trial: 26855665
Drug: Partially hydrolyzed
RxNorm normalized name: Human Skin Proteins, Partially Hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolyzed guar gum (PHGG) 6 g/day
Trial: 26856824
Drug: Dosage adjustments
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage adjustments
Trial: 26858336
Drug: NEOD001 (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEOD001 (24 mg/kg)
Trial: 26859538
Drug: Once-daily tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tiotropium 5 μg
Trial: 26859538
Drug: Twice-daily tiotropium
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tiotropium 2.5 μg
Trial: 26859761
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG-ATCC 53103 (LGG) treatment for 28 days
Trial: 26859761
Drug: Post-treatment (Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (Day 56)
Trial: 26861602
Drug: Everolimus added
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus added to trastuzumab and paclitaxel as first-line therapy
Trial: 26861740
Drug: Sorafenib (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200mg qd titrated to 400mg BID) with infusional 5-FU (225 mg/m(2)/24h) and radiation (28 fractions at 1.8 Gy)
Trial: 28282612
Drug: Imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800 mg daily for 2 years
Trial: 26861921
Drug: 75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg nonaqueous glucagon
Trial: 26861921
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg nonaqueous glucagon
Trial: 26861921
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg nonaqueous glucagon
Trial: 26861921
Drug: Post-insulin administration
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-insulin administration with 75 μg glucagon
Trial: 26861921
Drug: Post-insulin administration
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-insulin administration with 150 μg glucagon
Trial: 26861921
Drug: Post-insulin administration
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-insulin administration with 300 μg glucagon
Trial: 26863635
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with histamine dihydrochloride and low-dose interleukin-2